Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03861793
Brief Title: A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

First Submitted : February 25, 2019
First Submitted that Met QC Criteria : March 1, 2019
First Posted : March 4, 2019

Last Update Submitted that Met QC Criteria : February 1, 2022
Last Update Posted : February 3, 2022